| Business Summary | | Johnson
&
Johnson
is
engaged
in
the
manufacture
and
sale
of
a
broad
range
of
products
in
the
healthcare
field.
The
Company
conducts
business
in
virtually
all
countries
of
the
world.
Historically,
Johnson
&
Johnson's
primary
interest
was
in
products
related
to
human
health
and
well
being.
Johnson
&
Johnson's
worldwide
business
is
divided
into
three
segments:
Consumer,
Pharmaceutical
and
Professional.
In
June
2001,
the
Company
merged
with
ALZA
Corporation.
Under
the
terms
of
the
merger,
ALZA
Corporation
will
retain
its
name
and
survive
as
a
direct,
wholly
owned
subsidiary
of
Johnson
&
Johnson.
ALZA
Corporation
is
a
research-based
pharmaceutical
company
that
offers
drug
delivery
technologies.
ALZA
applies
its
delivery
technologies
to
develop
pharmaceutical
products
with
enhanced
therapeutic
value
for
its
own
portfolio
and
for
many
pharmaceutical
companies.
ALZA's
sales
and
marketing
efforts
are
focused
on
urology,
oncology
and
central
nervous
system
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Johnson
and
Johnson
is
a
manufacturer
of
heatlh
care
products
serving
the
consumer,
pharmaceutical
and
professional
markets.
For
the
six
months
ended
6/30/01,
revenues
rose
8%
to
$16.36
billion.
Net
income
rose
13%
to
$3.03
billion.
Revenues
reflect
a
strong
performance
of
PROCRIT/EPREX
and
RISPERDAL
and
an
increase
in
sales
of
skin
care
product
lines.
Net
income
reflects
improved
profit
margin
and
decreased
SG&A
expenses
as
a
percentage
of
sales. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Ralph Larsen, 62 Chairman,
CEO | $4.7M | $2.9M | James Lenehan, 52 Vice
Chairman Medical Devices & Diagnostics Group | 1.8M | 604K | William Weldon, 52 Vice
Chairman | 1.7M | 684K | Robert Wilson, 60 Sr.
Vice Chairman | 3.5M | 4.0M | Robert Daretta, 54 VP-Fin. | -- | -- | Dollar amounts are as of 3-Jan-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|